Investigational Drug Information for Defactinib
✉ Email this page to a colleague
What is the development status for investigational drug Defactinib?
Defactinib is an investigational drug.
There have been 24 clinical trials for Defactinib.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2013.
The most common disease conditions in clinical trials are Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, and Pancreatic Neoplasms. The leading clinical trial sponsors are Verastem, Inc., National Cancer Institute (NCI), and Merck Sharp & Dohme Corp.
Summary for Defactinib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 161 |
| WIPO Patent Applications | 118 |
| Japanese Patent Applications | 29 |
| Clinical Trial Progress | Phase 2 (2013-09-01) |
| Vendors | 65 |
Recent Clinical Trials for Defactinib
| Title | Sponsor | Phase |
|---|---|---|
| Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma | National Cancer Institute (NCI) | Early Phase 1 |
| Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma | Verastem, Inc. | Early Phase 1 |
| Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma | Emory University | Early Phase 1 |
Clinical Trial Summary for Defactinib
Top disease conditions for Defactinib
Top clinical trial sponsors for Defactinib
US Patents for Defactinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
